Compare PCB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | KMDA |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 385.3M |
| IPO Year | N/A | N/A |
| Metric | PCB | KMDA |
|---|---|---|
| Price | $21.49 | $7.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $24.50 | $13.00 |
| AVG Volume (30 Days) | 27.7K | ★ 95.1K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.71% | 2.69% |
| EPS Growth | ★ 43.50 | 30.41 |
| EPS | ★ 2.41 | 0.35 |
| Revenue | $107,743,000.00 | ★ $174,787,000.00 |
| Revenue This Year | $21.55 | $14.79 |
| Revenue Next Year | $8.65 | $10.74 |
| P/E Ratio | ★ $8.94 | $20.91 |
| Revenue Growth | ★ 13.61 | 10.36 |
| 52 Week Low | $16.00 | $5.54 |
| 52 Week High | $24.04 | $9.16 |
| Indicator | PCB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 71.72 |
| Support Level | $21.27 | $6.92 |
| Resistance Level | $22.24 | $7.17 |
| Average True Range (ATR) | 0.55 | 0.17 |
| MACD | -0.18 | 0.05 |
| Stochastic Oscillator | 9.19 | 78.33 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.